Medical Bulletin 26/September/2022
Here are the top medical news for the day:Transition to newer clot-busting drug improves patient outcomes and lowers treatment costA newer-generation clot-busting drug called Tenecteplase outperforms the traditional treatment for ischemic strokes in several key areas, including better health outcomes and lower costs, according to a new study published today in the American Stroke...
Login or Register to read the full article
Here are the top medical news for the day:
Transition to newer clot-busting drug improves patient outcomes and lowers treatment cost
A newer-generation clot-busting drug called Tenecteplase outperforms the traditional treatment for ischemic strokes in several key areas, including better health outcomes and lower costs, according to a new study published today in the American Stroke Association's journal Stroke.
Nearly 800,000 people in the United States have a stroke every year. The vast majority of those strokes (about 87%) are ischemic, meaning they occur when a vessel supplying blood to the brain is obstructed by a blood clot. This can result in a corresponding loss of neurologic function.
Reference:
Steven Warach et al,Tenecteplase As Stroke Thrombolytic in Practice,Stroke
Gut bacteria and metabolites strongly linked
There are strong links between bacteria living in the gut and the levels of small molecules in the blood known as metabolites. Such is the finding of a new study led by researchers from Uppsala University and Lund University, which is now published in the journal Nature Communications.
A team of scientists coordinated by Uppsala University and Lund University has found strong links between certain bacteria living in the gut and small molecules found in the blood. The study is based on analyses of both fecal and blood samples from 8,583 participants in the Swedish Cardio Pulmonary bioImage Study (SCAPIS).
Reference:
Tove Fall et al,An online atlas of human plasma metabolite signatures of gut microbiome composition,Nature Communications, DOI: 10.1038/s41467-022-33050-0
Acquired immunity against random food allergens may offer immunity against COVID-19 to few
A recent study in open-access journal Frontiers in Immunology finds that common foods, vaccines, bacteria and viruses may all prime our immune system to attack SARS-CoV-2, the virus that causes Covid-19. These agents all contain proteins that are similar to those found in SARS-CoV-2.
Proteins present in bacteria, human cells, vaccines, and even foods may all share similarities with those in SARS-CoV-2. The researchers behind this latest study hypothesized that similarities between SARS-CoV-2 and other common proteins may affect our susceptibility to the virus.
Reference:
Dr Aristo Vodjani et al,Frontiers in Immunology
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd